Abu Dhabi’s sovereign wealth fund has fully exited its minority stake in Arcadia Consumer Healthcare, coinciding with the company’s acquisition by funds managed by Bansk Group. Moreover, the fund had held its position for four years alongside Bansk, supporting the company’s rapid growth. Financial details of the transaction were not disclosed.
During this period, Arcadia’s revenue tripled, while profitability improved significantly. Additionally, strategic acquisitions of Avrio and CloSYS complemented organic growth, establishing the platform as a leading North American player in over-the-counter medicines, premium vitamins, and nutritional supplements. As a result, the company strengthened its position in a highly competitive consumer healthcare market.
Strategic Growth and Operational Impact
Philip Yifei Bao, Director of Private Equity at Mubadala, said, “It has been a privilege to partner with Bansk, Mike DeBiasi and the Arcadia team over the past four years. We are incredibly proud to have supported the transformation of Arcadia into the leading North American consumer health and wellness platform.” Moreover, he noted that the growth reflects the strength of the management team and the platform’s long-term trajectory.
Bart Becht, Senior Partner and Chairman at Bansk, added, “We would like to thank Mubadala for their partnership over the last four years. Their long-term perspective, active management style and commitment to responsible stewardship played a key role in accelerating Arcadia’s growth and setting the company up for sustained success.”
Market Position and Outlook
Arcadia remains one of the fastest-growing platforms in the US consumer healthcare sector. Additionally, the company benefits from strong brand recognition and an expanded product portfolio. Therefore, under Bansk’s stewardship, it is positioned for continued growth in both revenue and market share across OTC medicines and premium wellness products.
